摘要
目的探讨艾司西酞普兰合用奥氮平治疗更年期难治性抑郁症的治疗效果和不良反应。方法 61例更年期难治性抑郁症患者按照门诊和住院顺序用随机数字表分为艾司西酞普兰合用奥氮平治疗组(研究组)31例和单用艾司西酞普兰治疗组(对照组)30例。应用17项汉密尔顿抑郁评定量表(HAMD-17)评定疗效;应用不良反应量表(TESS)评定分析不良反应,同时对血糖、血脂和体重指数进行统计分析。结果治疗12周时研究组总有效率66.7%;对照组总有效率33.3%,两组治疗有效率差异有显著性(P<0.01)。HAMD-17评分研究组和对照组在治疗4周时与治疗前比较差异有显著性(P<0.05或P<0.01);两组间治疗前差异无显著性(P>0.05),在治疗4、6、8、12周比较差异有显著性(P<0.05或P<0.01)。TESS和糖脂代谢和体重统计两组不良反应发生率总体相当,差异无显著性(P>0.05)。结论艾司西酞普兰联合奥氮平治疗对处于更年期的难治性抑郁症患者可以提高疗效,而且安全性较好。
Objective To investigate the efficacy and adverse events of escitalopram combined with olanzapine in the treatment of menopausal refractory depression. Method Patients with menopause refractory depression in outpatient and hospitalization were randomly divided into two groups,namely escitalopram combined with olanzapine in the treatment group（ study group,n = 31） and single use of escitalopram in the treatment group（ control group,n = 30）.The treatment response was rated by the 17 Hamilton Depression Rating Scale（ HAMD-17）. The adverse reactions were evaluated by the Treatment Emergent Symptom Scale（ TESS）. In addition,the blood glucose,blood lipids and BMI were statistically analyzed. Result After 12 weeks treatment,the total response rate was 66. 7% and 33. 3% in the study group（ P〈0. 01）,and control group,respectively. No difference in HAMD-17 score was found at baseline.After being treated for 4,6,8 and 12 weeks,the HAMD-17 scores was significantly lower in the study group than control group（ P〈0. 05 or P〈0. 01）. The incidence of adverse events in TESS and the changes in glucose levels,lipid profile,and body weight were not statistically significant（ P〉0. 05） between the two groups. Conclusion The combination of olanzapine with escitalopram improves the treatment response in patients with menopausal refractory depression than escitalopram-only.
出处
《中国临床医生杂志》
2016年第6期28-30,共3页
Chinese Journal For Clinicians
